Tardive dyskinesia (TD) is a movement disorder that causes involuntary, repetitive movements, most often in the face, tongue, and jaw. It develops as a side effect of medications that block dopamine receptors in the brain, particularly antipsychotic drugs. The condition affects roughly 1 in 10 people taking antipsychotics, and it can persist even after the medication is stopped.
The name itself tells the story: “tardive” means delayed, and “dyskinesia” means abnormal movement. Unlike side effects that appear right away, TD typically emerges after months or years of taking the triggering medication.
What TD Looks and Feels Like
The hallmark of tardive dyskinesia is movements you can’t control. These most commonly involve the lower face: lip smacking, puckering, or pursing; repetitive chewing motions with nothing in the mouth; tongue thrusting or darting the tongue in and out; and jaw swinging or clenching. Rapid eye blinking and grimacing are also common.
But TD isn’t limited to the face. It can affect the fingers, producing what clinicians describe as “piano-playing” movements. It can show up in the legs as foot tapping, toe curling, or restless shifting. The trunk can be involved too, with rocking, twisting, or pelvic thrusting that changes the way a person walks. Some people experience mild symptoms they barely notice, while others find the movements severe enough to interfere with eating, speaking, or social interactions.
The severity varies widely. Some people are unaware of their movements until someone else points them out. Others experience significant distress. Clinicians track TD using a standardized tool called the Abnormal Involuntary Movement Scale (AIMS), which rates movements in the face, extremities, and trunk on a 0-to-4 scale from none to severe. Patients on antipsychotics are generally screened with this tool at least every six months.
Which Medications Cause It
The primary culprits are drugs that block dopamine receptors. Antipsychotics are by far the most common cause, but they aren’t the only one. Any medication that interferes with dopamine signaling in the brain’s movement-control pathways can potentially trigger TD.
Older antipsychotics, sometimes called first-generation or “typical” antipsychotics, carry the highest risk. A large meta-analysis of over 11,000 patients found that 30% of people taking first-generation antipsychotics developed TD, compared to about 21% of those on newer, second-generation (“atypical”) antipsychotics. The newer drugs carry less risk, but they are far from risk-free.
Certain anti-nausea medications also block dopamine and have been linked to TD, particularly when used long-term. The key factor across all these drugs is duration of use. Long-term treatment, especially with older antipsychotics, is the single strongest risk factor for developing the condition.
What Happens in the Brain
The exact mechanism behind TD isn’t fully understood, but the leading theory centers on how the brain adapts to having its dopamine signals chronically blocked. When a drug blocks dopamine receptors for months or years, the brain compensates by becoming more sensitive to dopamine. It essentially turns up the volume on the receptors that are being blocked, a process called receptor upregulation.
This creates a problem. The movement-control circuits in the brain depend on a careful balance of dopamine signaling. When receptors become hypersensitive, even normal amounts of dopamine can overstimulate those circuits, producing involuntary movements. It’s somewhat like turning up a microphone’s sensitivity so high that it picks up every background noise.
Other mechanisms likely contribute. Prolonged antipsychotic use may damage certain inhibitory brain cells that normally keep movements in check, and there’s evidence that oxidative stress (a form of cellular damage from unstable molecules) plays a role in the nerve injury that makes TD persistent. This is part of why TD can continue even after the triggering medication is discontinued: the underlying changes in the brain’s wiring may already be established.
Who Is Most at Risk
Not everyone on antipsychotics develops TD, and certain factors raise the odds significantly. The most important ones include:
- Duration of medication use. The longer you take a dopamine-blocking drug, the greater the risk. This is consistently the strongest predictor.
- Type of antipsychotic. First-generation antipsychotics carry roughly 50% higher risk than second-generation ones.
- Age. Older adults are considerably more vulnerable. Prevalence data shows that Medicare-age patients on antipsychotics have TD rates around 12.7%, compared to about 9.4% in younger commercially insured populations.
- Sex. Women, particularly postmenopausal women, appear to be at higher risk.
- Other health conditions. Diabetes and cognitive impairment have both been identified as independent risk factors. One study found that cognitive decline actually preceded TD onset, suggesting it may signal vulnerability rather than being a consequence.
- Race. Some research indicates that Black patients face disproportionately higher rates, though this may partly reflect differences in prescribing patterns and access to newer medications.
How TD Is Treated
For years, there were no approved treatments specifically for TD. That changed in 2017 with the approval of two medications that work by reducing the amount of dopamine available in the brain’s movement circuits. Rather than blocking dopamine receptors (which is what caused the problem), these drugs limit how much dopamine gets packaged and released by nerve cells.
One is taken once daily; the other twice daily. Both have shown meaningful reductions in involuntary movements in clinical trials, with patients experiencing roughly twice the improvement of those on placebo over 6 to 12 weeks. These aren’t cures. They manage symptoms, and the movements can return if the medication is stopped. But for many people, the reduction in visible movements significantly improves quality of life and reduces social embarrassment.
The trickier question is what to do about the antipsychotic that caused the problem. Simply stopping it isn’t always an option, because the psychiatric condition it treats (often schizophrenia or bipolar disorder) may be far more dangerous untreated. In some cases, switching to a lower-risk antipsychotic or reducing the dose helps. These decisions require careful balancing of risks, and the approach looks different for every patient.
Can TD Be Reversed?
The earlier TD is caught, the better the chances of improvement. When the condition is identified quickly and the triggering medication is adjusted, symptoms sometimes resolve on their own, particularly in younger patients. This is why regular screening matters so much for anyone on long-term antipsychotics.
In cases where TD has been present for years, full reversal is less likely. The brain changes underlying the condition can become entrenched over time. That said, even long-standing TD often responds to the newer targeted medications, with many patients seeing significant symptom reduction even if complete resolution isn’t achieved. The condition is no longer considered untreatable, which represents a meaningful shift from just a decade ago.